Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 and/or MBG453 with decitabine or azacitidine in AML or high-risk MDS
NL-OMON55557Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of spartalizumab, sabatolimab, decitabine and azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and 1 more (8 arms), sponsored by Novartis. Primary endpoints: Adverse events and Dose-limiting toxicities. Started Feb 2019; status: active, not recruiting.
02
Drugs
spartalizumabsabatolimabdecitabineazacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NL-OMON55557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55557.